NCT02588131View on ClinicalTrials.gov

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

March 31, 2018

Conditions

Pleural MesotheliomaPeritoneal Mesothelioma

Interventions

DRUG

tremelimumab plus MEDI4736

tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.

Trial Locations (1)

53100

RECRUITING

Medical Oncology and Immunotherapy Division, University Hospital of Siena, Siena